D3 Pharma and Encap Drug Delivery Continue Partnership

Livingston, United Kingdom, June 18 2012 / B3C newswire / - D3 Pharma Limited today announces its continuing partnership with Encap Drug Delivery to expedite the commercial manufacturing and product licensing programme for its proprietary high-dose oral vitamin D₃ product, Plenachol™, for the treatment of vitamin D deficiency and insufficiency.

Plenachol™ is a patented liquid-filled capsule formulation of vitamin D₃ which was developed in conjunction with Encap and is available at three dose-strengths: 20,000, 40,000 and 100,000 international units. Plenachol™ has a unique formulation base which is free from animal derived excipients and peanut constituents. The utility of Encap’s world-class capsule liquid-filling technology secures Plenachol™ as a first and best-in-class high-dose oral vitamin D₃ product.  

Plenachol™ will continue to be made available as a Specials product during the pre-license phase via Encap Drug Delivery. For more information regarding Plenachol™ Specials supply please contact: Dr Janice McLachlan ( This e-mail address is being protected from spambots. You need JavaScript enabled to view it ).


About D3 Pharma
D3 Pharma is a privately owned specialty pharmaceutical company based in the United Kingdom. It is committed to the research, development and commercialisation of licensed high-dose vitamin D₃ medicinal products for the treatment of vitamin D deficiency, insufficiency and associated conditions. D3 Pharma’s pioneering work in the vitamin D deficiency area aims to address a significant unmet need and improve vitamin D product access world-wide.

About Encap Drug Delivery
Encap Drug Delivery is the world’s largest contract development and manufacturing organization (CDMO) totally dedicated to liquid and semi-solid (hot melt) filled capsules. The company was established in 1989 and is a global provider of oral drug delivery and pharmaceutical development services. The company provides clients with fully integrated analytical and formulation development services, clinical trial manufacturing and high volume commercial manufacturing. Encap’s state-of-the-art facility in the UK has been audited by the FDA and MHRA and supplies clinical and commercial products to all major global markets including EU, North and South America and Japan.


Contacts:

Dr Hiep Huatan
D3 Pharma Ltd
+44 1622 630057
or
Dr Stephen Brown
Encap Drug Delivery
+44 1506 448080